Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 13/20 | 0.34 |
| ▸ | PLG | P00747 | 8/20 | 0.34 |
| ▸ | F2 | P00734 | 8/20 | 0.34 |
| ▸ | PLAT | P00750 | 8/20 | 0.34 |
| ▸ | F10 | P00742 | 3/20 | 0.33 |
| ▸ | KLK8 | O60259 | 2/20 | 0.32 |
| ▸ | KLK2 | P20151 | 2/20 | 0.32 |
| ▸ | KLK4 | Q9Y5K2 | 2/20 | 0.32 |
| ▸ | KLK1 | P06870 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737941 | 1.00 | PLAU (0.34) | PLAUPLGF2PLATF10 | |
| SCHEMBL13737828 | 0.91 | PLAU (0.34) | PLAUPLGF2PLATF10 | |
| SCHEMBL13738337 | 0.90 | PLAU (0.39) | PLAUPLGF2PLATF10 | |
| SCHEMBL13738392 | 0.87 | PLAU (0.35) | PLAUPLGF2PLATF10 | |
| SCHEMBL13736386 | 0.87 | PLAU (0.35) | PLAUPLGF2PLATF10 | |
| SCHEMBL15523000 | 0.86 | PLAU (0.35) | PLAUPLGF2PLATF10 | |
| SCHEMBL13739815 | 0.83 | PLAU (0.36) | PLAUPLGF2PLATF10 | |
| Trifluoroacetic Acid SCHEMBL13737939 | 0.82 | PLAU (0.50) | PLAUPLGF2PLATF10 | |
| Trifluoroacetic Acid SCHEMBL13736716 | 0.82 | PLAU (0.50) | PLAUPLGF2PLATF10 | |
| SCHEMBL13736076 | 0.82 | PLAU (0.32) | PLAUPLGF2PLATF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2014-03-20 | — | — | US | disclosed |
| EP-2707034-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | Universiteit Antwerpen (BE) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012152807-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | PLAU, SERPINE1, PRSS3 | PLAU 1/4885PLG 8/4885F2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.